Not recruiting

Study on Long-term Safety of Apremilast in Children Aged 6-17 with Moderate to Severe Plaque Psoriasis

Fast replyRegistered drug

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial is focused on studying the long-term safety of a medication called Apremilast (also known by its code name CC-10004) in children and teenagers aged 6 to 17 who have moderate to severe plaque psoriasis. Plaque psoriasis is a skin condition that causes red, scaly patches to appear on the skin. The medication being tested, Apremilast, is taken in the form of film-coated tablets.

The purpose of the study is to evaluate how safe Apremilast is for young patients over an extended period. Participants in the study will take the medication orally, and the study will monitor them for any side effects or changes in their health. The study will also keep track of their growth, including height and weight, and assess their development over time. Additionally, the study will use a questionnaire to monitor any changes in mood or behavior, such as depression or suicidal thoughts.

Throughout the study, participants will have regular check-ups to ensure their well-being and to gather information on how the medication affects them. The study aims to provide valuable insights into the long-term use of Apremilast in treating plaque psoriasis in young people, helping to determine its safety and effectiveness for this age group.

The research process

The trial runs in 4 steps – from screening to follow-up. Each step says what happens and what the team monitors.

Step 1
Initial visit
Upon joining the study, you will attend an initial visit. During this visit, your height, weight, and body mass index (BMI) will be measured. These measurements help monitor your growth throughout the study.
You will also undergo an assessment of your sexual maturity, known as Tanner Staging. This assessment will be repeated every 52 weeks and at the end of the study if you leave early.
A questionnaire called the Columbia-Suicide Severity Rating Scale (C-SSRS) will be used to monitor your mood and any thoughts of self-harm. This will be done throughout the study.
Step 2
Medication administration
You will be given a medication called Otezla, which comes in the form of film-coated tablets. The tablets are taken by mouth.
The dosage of Otezla will be 10 mg, 20 mg, or 30 mg, depending on your specific needs as determined by the study team.
You will take the medication as directed by the study team, and the duration of administration will be explained to you during the study.
Step 3
Regular follow-up visits
You will have regular follow-up visits where your height, weight, and BMI will be measured again to monitor your growth.
The Tanner Staging assessment will be repeated every 52 weeks to track any changes in your sexual maturity.
The C-SSRS questionnaire will continue to be used to monitor your mood and any thoughts of self-harm.
Step 4
End of study
At the end of the study, or if you leave early, you will have a final visit. During this visit, your height, weight, and BMI will be measured one last time.
The Tanner Staging assessment will be conducted again to provide a final evaluation of your sexual maturity.
The C-SSRS questionnaire will be completed to ensure your mood and thoughts are stable.

Who can join the trial?

5 criteria

The participant must be a boy or girl aged between 6 and 17 years old.
The participant must weigh at least 20 kilograms (about 44 pounds).
The participant's Body Mass Index (BMI), which is a measure of body fat based on height and weight, must be no lower than the 5th percentile according to the Centers for Disease Control (CDC) growth chart for children and adolescents.
The participant must have completed Week 52 of a previous study called Study CC-10004-PPSO-003.
The participant must be able to sign an assent form, which is a document showing they agree to participate, and have a legal guardian who understands and signs an informed consent form before any study-related activities are done.

Who cannot join the trial?

9 criteria

Patients who do not have moderate to severe plaque psoriasis cannot participate. Plaque psoriasis is a skin condition that causes red, scaly patches on the skin.
Children younger than 6 years old and older than 17 years old cannot participate.
Patients who are not comfortable with the long-term use of the study medication cannot participate.
Patients who are not willing to follow the study procedures cannot participate.
Patients who have other health conditions that might interfere with the study cannot participate.
Patients who are currently participating in another clinical trial cannot participate.
Patients who have had a recent infection or illness that could affect the study cannot participate.
Patients who are pregnant or breastfeeding cannot participate.
Patients who have a history of allergic reactions to the study medication cannot participate.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Responsive
Cliniques Universitaires Saint-Luc
Woluwe-Saint-Lambert, Belgium
Responsive
Fakultni Nemocnice Kralovske Vinohrady
Prague, Czechia
Responsive
Fundacion Para La Investigacion Biomedica Del Hospital Universitario La Paz
Madrid, Spain

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not recruiting

Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

Apremilast is a medication used in this clinical trial to help manage moderate to severe plaque psoriasis in children and adolescents aged 6 to 17 years. Plaque psoriasis is a skin condition that causes red, scaly patches to appear on the skin. Apremilast works by reducing inflammation in the body, which can help decrease the symptoms of psoriasis, such as redness and scaling. This study aims to evaluate the long-term safety of using Apremilast in young patients, ensuring that it is a safe option for managing their condition over an extended period.

What is already known about the treatment

Apremilast – Apremilast is taken orally in the form of a tablet. It is currently being studied in clinical trials for its long-term safety in children and adolescents aged 6 to 17 years with moderate to severe plaque psoriasis. This medication is primarily used to treat moderate to severe plaque psoriasis, a skin condition that causes red, scaly patches. At the molecular level, apremilast works by inhibiting an enzyme called phosphodiesterase 4 (PDE4), which helps reduce inflammation in the body. It is classified as a phosphodiesterase inhibitor in pharmacology.

Investigated diseases

Moderate to Severe Plaque Psoriasis – Plaque psoriasis is a chronic autoimmune condition characterized by the rapid growth of skin cells, leading to the formation of thick, red, scaly patches or plaques on the skin. These plaques often appear on the elbows, knees, scalp, and lower back, but they can occur anywhere on the body. The disease progresses through cycles, with periods of flare-ups followed by times of remission. During flare-ups, the plaques can become itchy, painful, and may crack or bleed. The severity of the condition can vary, with moderate to severe cases involving more extensive skin coverage and more significant impact on quality of life. The exact cause of plaque psoriasis is not fully understood, but it involves a combination of genetic, immune, and environmental factors.